An exploratory first‐in‐man study to investigate the pharmacokinetics and safety of liposomal dexamethasone at a 2‐ and 1‐week interval in patients with metastatic castration resistant prostate cancer

Josephina P. M. Vrouwe, Ingrid M. C. Kamerling, Michiel J. van Esdonk, Josbert M. Metselaar, Frederik E. Stuurman, Gabri van der Pluijm, Jacobus Burggraaf, Susanne Osanto

Open source

DOI
10.1002/prp2.845
Published
2021-08-20
Container
Pharmacology Research & Perspectives
Publisher
Wiley
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1002/prp2.845,
  title = {An exploratory first‐in‐man study to investigate the pharmacokinetics and safety of liposomal dexamethasone at a 2‐ and 1‐week interval in patients with metastatic castration resistant prostate cancer},
  author = {Josephina P. M. Vrouwe and Ingrid M. C. Kamerling and Michiel J. van Esdonk and Josbert M. Metselaar and Frederik E. Stuurman and Gabri van der Pluijm and Jacobus Burggraaf and Susanne Osanto},
  year = {2021},
  journal = {Pharmacology Research \& Perspectives},
  doi = {10.1002/prp2.845},
  url = {https://doi.org/10.1002/prp2.845}
}

RIS

TY  - JOUR
TI  - An exploratory first‐in‐man study to investigate the pharmacokinetics and safety of liposomal dexamethasone at a 2‐ and 1‐week interval in patients with metastatic castration resistant prostate cancer
AU  - Josephina P. M. Vrouwe
AU  - Ingrid M. C. Kamerling
AU  - Michiel J. van Esdonk
AU  - Josbert M. Metselaar
AU  - Frederik E. Stuurman
AU  - Gabri van der Pluijm
AU  - Jacobus Burggraaf
AU  - Susanne Osanto
PY  - 2021
JO  - Pharmacology Research & Perspectives
DO  - 10.1002/prp2.845
UR  - https://doi.org/10.1002/prp2.845
ER  - 

APA

Vrouwe, J. P. M., Kamerling, I. M. C., Esdonk, M. J. V., Metselaar, J. M., Stuurman, F. E., Pluijm, G. V. D., Burggraaf, J., & Osanto, S. (2021). An exploratory first‐in‐man study to investigate the pharmacokinetics and safety of liposomal dexamethasone at a 2‐ and 1‐week interval in patients with metastatic castration resistant prostate cancer. Pharmacology Research & Perspectives. https://doi.org/10.1002/prp2.845

Source records